Cowen

Bevi develops a smart water dispenser that provides customizable flavors made from filtered tap water and natural ingredients. Bevi aims to eliminate waste from the production, shipping, and disposing of bottled beverages. Bevi envisions a future where a smarter platform (powered by the municipal water supply) transforms how beverages are delivered.

Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Digital Prime Technologies is a provider of customizable prime brokerage technology solutions for financial institutions. Its all-in-one user interface leverages both API and SaaS product offerings to connect clients with a growing network of liquidity providers to transact, borrow, and lend digital assets and manage collateral.

AlphaSense, Inc. is a market intelligence platform that specializes in information discovery for research professionals. Founded in 2007 and headquartered in New York, the company operates additional offices in London, Helsinki, Pune, and the U.S. Its platform allows users to efficiently search and analyze a wide range of financial data, including filings, research reports, and news, by utilizing natural language processing and advanced search algorithms. With nearly 2,000 enterprise clients, including a significant number of S&P 500 companies, AlphaSense empowers organizations to make informed business decisions quickly and confidently. The platform's capabilities include setting alerts and navigating through vast amounts of data to extract crucial insights across various industries.

Quip NYC, Inc., known as quip, is an oral healthcare company based in Brooklyn, New York, that designs, manufactures, and sells a range of oral care products. Founded in 2014, quip offers electric toothbrushes, toothpaste, and refillable floss options, along with accessories like toothbrush heads and travel covers. The company is notable for its direct-to-consumer subscription service, which provides customers with fresh supplies every three months. In addition to its product offerings, quip aims to enhance the oral care experience by delivering advice and services, and is developing technology to connect users with dental professionals. The company primarily sells its products through its online platform, making oral health more accessible and enjoyable for consumers.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through a network of automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, California, ecoATM simplifies the process of selling unwanted electronics by offering consumers cash on the spot for their devices. The kiosks evaluate the worth of these used items, transforming them into valuable materials such as copper, silver, gold, or palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing the customer experience with both online and kiosk options for trading in pre-owned electronics. Positioned in high-traffic areas like malls and grocery stores, ecoATM kiosks provide a convenient, safe, and efficient means for consumers to engage in responsible recycling while receiving immediate compensation for their used devices. Additionally, Gazelle.com offers certified pre-owned devices, providing consumers with quality options at competitive prices.

PolySign develops state-of-the-art, secure, scalable infrastructure for financial institutions to fully leverage their digital assets. The company also develops a secure and scalable infrastructure for financial institutions to fully leverage their digital assets. They aim to integrate with existing financial organizations and global markets, and rigorously embrace the highest standards for regulation.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Proterra designs and manufactures zero-emission, heavy-duty electric vehicles, enabling bus fleet operators to significantly reduce operating costs while delivering clean, quiet transportation to local communities across North America. The company’s configurable Catalyst platform is designed to serve the daily mileage needs of a wide range of transit routes on a single charge. With industry-leading durability and energy efficiency based on rigorous U.S. independent testing, Proterra products are proudly designed, engineered, and manufactured in America, with offices in Silicon Valley, South Carolina, and Los Angeles. Proterra's revolutionary battery-electric transit vehicles help fleet operators abandon fossil fuels, improve environmental quality, and reduce operating costs. Together with their customers, they have prevented more than 55 million pounds of greenhouse gases from escaping into the atmosphere and avoided burning some 2 million gallons of fuel. The company was established in 2004 and is based in Burlingame, California, USA.

Kyber Data Science LLC is a subsidiary of Cowen Inc. focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations.

ecoATM, LLC specializes in the recycling of electronic devices, including cell phones, tablets, and MP3 players, through a network of automated kiosks located throughout the United States. Founded in 2008 and based in San Diego, California, ecoATM simplifies the process of selling unwanted electronics by offering consumers cash on the spot for their devices. The kiosks evaluate the worth of these used items, transforming them into valuable materials such as copper, silver, gold, or palladium. In 2015, ecoATM expanded its services by acquiring Gazelle, enhancing the customer experience with both online and kiosk options for trading in pre-owned electronics. Positioned in high-traffic areas like malls and grocery stores, ecoATM kiosks provide a convenient, safe, and efficient means for consumers to engage in responsible recycling while receiving immediate compensation for their used devices. Additionally, Gazelle.com offers certified pre-owned devices, providing consumers with quality options at competitive prices.

Cowen Inc. is a financial services firm that provides a range of investment banking, research, sales and trading, and investment management services in the United States and internationally. The company operates through two segments: Operating Company and Asset Company. It assists both public and private entities with capital raising and strategic advisory services, including mergers and acquisitions. Cowen engages in trading various financial instruments on behalf of institutional clients and offers comprehensive prime brokerage services, global execution, and clearing solutions. The firm also provides in-depth research and analysis across multiple sectors, including healthcare, technology, and consumer industries. In addition to its investment banking services, Cowen manages alternative investment products for institutional and private clients. Established in 1918 and headquartered in New York, Cowen has a global presence that includes offices in Europe, focusing on middle-market companies and facilitating equity and debt capital raises.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

As a leading technology firm, they provide mission critical software products and technology-enabled services to more than 6,000 clients in 100 markets. Their large and diverse client base of asset managers and financial intermediaries includes investment advisors, hedge funds, mutual funds, plan sponsors, trust banks, family offices, separately managed accounts, broker-dealers, exchanges, alternative trading systems, and investment banks.

CEFC China Energy Company Limited (hereinafter referred to as “CEFC China”) is a private collective enterprise with energy and financial services as its core business. The strategy of the Company seeks to expand international economic cooperation in the energy sector and establish a well-organized international investment bank and an investment group.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 trials for extensive-stage small cell lung cancer (SCLC) and Phase 2 trials for first-line SCLC and metastatic triple-negative breast cancer. Additionally, G1 Therapeutics is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company partners with Quantum Leap Healthcare Collaborative to explore trilaciclib for neoadjuvant treatment of locally advanced breast cancer. Founded in 2008 and based in Research Triangle Park, North Carolina, G1 Therapeutics aims to address unmet needs in oncology through its novel therapeutic approaches.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that focuses on providing integrated solutions for individuals with chronic conditions, particularly diabetes. Founded in 2008, Livongo combines advanced technology with personalized coaching to empower users in managing their health. Its platform includes cellular-connected devices and data-driven insights, facilitating real-time support for diabetes management while also addressing hypertension, prediabetes, weight management, and behavioral health. Livongo serves a diverse clientele, including employers, health plans, government entities, and labor unions, aiming to improve both clinical outcomes and user experience in chronic disease management. In 2020, Livongo became a subsidiary of Teladoc Health, further expanding its reach in the healthcare market.

Quarton Partners, headquartered in Birmingham, Michigan, is a premier middle market investment banking firm, serving privately held and publicly traded companies, as well as private equity firms. Quarton Partners assists its clients with mergers and acquisitions, private capital raising, and other financial advisory services. Its principals have successfully completed hundreds of engagements in a wide variety of industries across the U.S. and throughout the world.

BlueCF is one of the leading independent corporate finance companies for mid size transactions in Europe. We advise entrepreneurs, companies and investors on corporate sales and financing topics. Since 2001 BlueCF has advised 180 clients in transactions with a total transaction value of over 4 bn. Euro.

Conifer Securities is a company that was acquired by Cowen Group in 2015

Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada.

Maxwell Technologies is in developing, manufacturing and marketing energy storage and power delivery solutions for automotive, heavy transportation, renewable energy, backup power, wireless communications and industrial and consumer electronics applications as well as for radiation-hardened microelectronic components and systems for satellites and spacecraft. Maxwell products are designed and built to provide failure-free performance for the life of the most demanding applications.

Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its antibody-coupled T-cell receptor technology, is expected to enter Phase I clinical testing in the coming months to assess safety and efficacy.

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.

Echo Global Logistics is a leading provider of technology-enabled business process outsourcing, serving the transportation and logistics needs of their clients. Their proprietary web-based technology, dedicated service teams and robust procurement power enables their clients to see significant transportation savings while receiving best-in-class service.

Seabridge Gold Inc. is a company focused on the acquisition and exploration of gold properties primarily located in North America. Its portfolio includes some of the largest undeveloped gold projects globally, particularly the Kerr-Sulphurets-Mitchell property in British Columbia, which is noted for its substantial gold and copper reserves. Seabridge aims to enhance shareholder value by increasing the ownership of resources and reserves per share through a risk-reduced strategy that involves acquiring deposits, expanding them through exploration, and advancing them to the stage of reserves. The company is also committed to environmental stewardship and community engagement, working to support local communities while minimizing its environmental impact. In addition to its main projects, Seabridge has several other mineral resource initiatives across North America.

Aptose Biosciences Inc. is a clinical-stage biotechnology company dedicated to discovering and developing personalized therapies for unmet medical needs in oncology. The company focuses on small molecule cancer therapeutics, with a pipeline that includes APTO-253, currently in a Phase 1b trial for patients with relapsed/refractory blood cancers such as acute myeloid leukemia and high-risk myelodysplastic syndrome. Additionally, Aptose is collaborating with CrystalGenomics, Inc. on CG026806, which is in a Phase 1a/b trial for relapsed/refractory acute myeloid leukemia and various B-cell malignancies. Another partnership with OHM Oncology involves the development and commercialization of APL-581 for the treatment of hematologic malignancies. Founded in 1986 and headquartered in Toronto, Canada, Aptose Biosciences was previously known as Lorus Therapeutics Inc. and changed its name in August 2014.

Solar3D is developing a breakthrough 3-dimensional solar cell technology to maximize the conversion of sunlight into electricity. Up to 30% of incident sunlight is currently reflected off the surface of conventional solar cells, and more is lost inside the solar cell materials. Inspired by light management techniques used in fiber optic devices, their innovative solar cell technology utilizes a 3-dimensional design to trap sunlight inside micro-photovoltaic structures where photons bounce around until they are converted into electrons. This next generation solar cell will be dramatically more efficient, resulting in a lower cost per watt that will make solar power affordable for the world.

InterDigital Communications, LLC, based in King Of Prussia, Pennsylvania, specializes in designing and developing advanced digital wireless technology solutions. As a subsidiary of InterDigital, Inc., the company focuses on research and development in areas such as wireless communication, video, and artificial intelligence. InterDigital's innovations aim to create connected and immersive experiences across various communications and entertainment products and services. The company's revenue primarily comes from fixed-fee patent license agreements, supplemented by variable royalty agreements. Geographically, InterDigital operates in multiple regions, including the United States, China, South Korea, Japan, Taiwan, and Europe, with a significant portion of its revenue generated from the Chinese market.

Sesen Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on their Targeted Protein Therapeutics (TPTs) platform. Their TPTs genetically combine targeting antibody fragments with cytotoxic protein payloads to create a single fusion protein through Eleven's proprietary one-step manufacturing process.

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.

Horizon Therapeutics operates as a biopharmaceutical company. It focuses on the development of prescription drugs for mild to moderate pain relief and arthritis. The company's product candidates include HZT-501, a proprietary fixed-dose combination formulation of NSAID and ibuprofen; and HZT-602, a combination oral drug product consisting of naproxen and famotidine. Horizon Therapeutics is based in Northbrook, Illinois, and was founded in 2005.

GlassesOff is a health care technology company providing consumer-oriented software apps to improve near vision sharpness. The company had developed a non-invasive product helping people suffering from Presbyopia to improve their near vision. It was founded in 2007 and headquartered in Hod Hasharon, HaMerkaz.

Dahlman Rose & Company, LLC is a research-driven investment bank focused on transportation, infrastructure, and industries that compose the global supply chain. The Company provides institutional sales and trading, equity and fixed income research, mergers and acquisitions advisory, and underwriting services. Dahlman Rose is headquartered in New York and has offices in Boston, Houston, and San Francisco.

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing therapeutic products for cancer treatment. The company's lead product candidate, tucatinib, is an orally active, HER2-selective small molecule tyrosine kinase inhibitor currently undergoing two Phase Ib clinical trials for metastatic breast cancer, one in combination with T-DM1 and the other with capecitabine and/or trastuzumab. In addition to tucatinib, Cascadian is advancing two preclinical candidates: CASC-578, a Chk1 cell cycle inhibitor, and CASC-674, an antibody targeting immuno-oncology. The company has established collaborations for research and development, including a licensing agreement with Array BioPharma for tucatinib, a research partnership with Sentinel Oncology to discover novel Chk1 inhibitors, and a collaboration with Adimab for novel antibody development. Formerly known as Oncothyreon Inc., Cascadian Therapeutics was founded in 1985 and has undergone significant evolution in its focus and offerings.

Aurora Flight Sciences, based in Manassas, Virginia, specializes in the design and manufacture of aerospace vehicles for both commercial and military applications. The company operates production facilities in Bridgeport, West Virginia, and Columbus, Mississippi, along with a Research and Development Center in Cambridge, Massachusetts. Aurora focuses on developing unmanned systems and high-altitude, long-endurance autonomous aircraft. It also innovates in various fields, including aircraft configurations, autonomous systems, propulsion technologies, and manufacturing processes. By applying advanced technologies and materials, Aurora aims to enhance the future of flight for government and commercial airline customers.

Reef is a provider of internet software applications for the management of e-business.

Nextest Systems Corporation, founded in 1997, specializes in the design and manufacture of automatic test equipment (ATE) for non-volatile memory, microcontrollers, ASICs, and system-on-a-chip (SOC) semiconductors. The company focuses on providing cost-effective solutions that enhance throughput, reliability, functionality, and capacity for manufacturers, all while minimizing testing costs and expediting time to market. With a workforce of around 150 employees and sales and support offices located globally, Nextest has established a significant presence in the testing equipment industry, having shipped over 1,000 systems worldwide since its inception.

D-Pharm (TASE: DPRM) is a drug-development company focused on innovative drugs for the treatment of central nervous system (CNS) conditions. The Company’s particular area of interest is in developing innovative medicine for degenerative and age-related disorders.

SiberCore Technologies Incorporated is a pure-play, Internet IC company developing high-value-added Application Specific Standard Products (ASSPs) for intelligent hardware-based switching and routing platforms, such as Gigabit / Terabit Routers and Layer 2 / 3 / 4 Ethernet Switches. The company's initial products are a family of high-speed high-capacity packet forwarding engines based on Content Addressable Memories (CAM technology) which overcome the performance bottleneck associated with the network's routing table look-up function. This emerging market has been created by the demands of the explosion in datacom traffic, coupled with the worldwide deployment of fiber optics and DWDM. These broadband deployments have shifted the bottleneck from the Access and Transport section of the network, to the Routers and Switches connecting to these pipes. The company's founding technical team gained industry-wide recognition for its world-class design expertise in this area at Nortel Networks. A veteran Executive team in all the functional divisions of the company supplements this preeminent technical team.

TelOptica was funded in 1999 by communications network experts in optical, next-generation network design engineering and in operations research and algorithm development. The TelOptica team today includes highly regarded technologists with experience from established telco giants such as MCI and Sprint, international original equipment manufacturers such as Alcatel / DSC, Nortel, and IBM, and management consulting firms including McKinsey and Associates and Carreker Corporation. TelOptica is a well-funded, fast growing, privately held, optical communications technology company. TelOptica incorporated in Texas , received initial funding and support from the Startech business incubator of Richardson, Texas, and closed on its second round of funding from Trellis Partners, Austin Ventures, Centerpoint Ventures, SSM Ventures of Austin, and SG Cowen in June 2001.

The company provides enterprise portal software for the deployment and management of Intranet and extranet portals. The company's Coreport enterprise portal software allows businesses to provide all their stakeholders with a single, secure point of unified and personalized access to content, applications, processes, and services from any wired or wireless device.

ThoughtWorks, Inc. is a global technology consultancy based in Chicago, Illinois, specializing in software delivery, tools, and consulting for organizations across commercial, social, and government sectors. Founded in 1993, the company integrates strategy, design, and software engineering to support digital innovation and transformation. Its offerings include project management tools like Mingle, continuous delivery solutions such as Go, and cloud deployment tools like Snap, as well as test automation with Twist. ThoughtWorks emphasizes agile practices to help clients continuously improve their software quality. The company is committed to social impact, collaborating with organizations that have humanitarian missions to leverage technology for positive change. With a diverse and inclusive culture, ThoughtWorks fosters an environment where ideas and integrity are prioritized, aiming to create a socially and economically just world through the power of software and technology.

With more than 15 million page-views and more than 700,000 unique users per month, IPO.COM is the leading Internet provider of content and services to investors interested in initial public offerings, private placements and emerging growth companies. The company provides comprehensive IPO content including offering summaries, up-to-date pricing and filings, searchable EDGAR documents, daily columns and free weekly e-mail newsletters through the company's interactive portal and more than 150 financial web sites. Privately held, IPO.COM has offices in New York, Pennsylvania and California.

Tripod is a web publishing service based in Williamstown, Massachusetts, that enables users to create fully functional websites using professional templates and powerful plugins. The company provides a range of tools designed to simplify the website development process, allowing clients to easily build sites tailored to their needs. In addition to its core offerings, Tripod also provides value-added services, including Search Engine Optimization, theme development by professional web designers, and plugin development. Furthermore, seasoned engineers offer site migration services, ensuring that users can effectively transition their existing websites to the Tripod platform.